ERBB2 and breast carcinoma: Of the 19 breast cancer patients, 95% were ER-positive and 26% were HER2-positive, while 81% and 19% of the lung cancer patients were diagnosed with non-small cell lung carcinoma (NSCLC) and small cell lung carcinoma (SCLC), respectively.